Lung Cancer Survivor Kathy Weber
Takes Super Bowl Challenge

UPDATE: Efforts Send Kathy to Pro Bowl

Save the Date for WCLC 2016
December 4-7, 2016

Registration Opens Soon


Find CME Information
for WCLC 2015

How to get your CME Certificate /
Certificate of Attendance

We are a global network of specialists working together to conquer lung and thoracic cancers worldwide.

Access WCLC 2015
Virtual Library now.

Featured Science and Communiqués

Afatinib Shows Clinical Benefit for Lung Cancer Patients with Brain Metastases

DENVER – Non-small cell lung cancer (NSCLC) patients with common epidermal growth factor (EGFR) mutations and brain metastases showed improved progression-free survival (PFS) and response from the EGFR tyrosine kinase inhibitor (TKI) afatinib compared to standard platinum doublet chemotherapy.

Stage Increase in Lung Cancer More Frequent After Open vs. Closed Thoracic Surgery

DENVER – An increase in the stage of non-small cell lung cancer (NSCLC) due to cancer positive lymph node (LN) discovery was more common following open chest surgery for lung lobe removal of early stage lung cancer compared to the closed chest procedure known as video assisted thoracic surgery (VATS).

Improving Access to Clinical Trials When Biopsies Are Required

DENVER – The requirement for tumor tissue specimens and associated analyses in order to participate in clinical trials appears to be a significant barrier to clinical trial enrollment and may delay treatment. Potential solutions to reducing or eliminating these barriers include routine tissue banking at diagnosis, easing use of available diagnostic samples, development of less invasive tests, faster turnaround time at central laboratories or allowing for local testing and more resources for timely tissue collection.

FDA Continues Recent Trend of Approval with New 2nd Generation Lung Cancer Treatment

IASLC Excited About Continued Advances in Treatment

DENVER – The International Association for the Study of Lung Cancer (IASLC) is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients in their battle against the disease. Lung cancer patients got another round of hope with the FDA’s rapid progression of lung cancer drug approvals – this time for alectinib (Alecensa, Roche/Genenetech) for patients with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) if their disease deteriorated after treatment with another therapy called crizotinib (Xalkori, Pfizer). Patients who could not tolerate treatment with crizotinib also qualify for use of alectinib.